Table 1.
Characteristics of patients (n = 18 236) detected with one or more respiratory viruses
| HAdY | HPIYs | HRSVs | IFYs | HCoYs | HRV | HBoV | HMPV | |
|---|---|---|---|---|---|---|---|---|
| Characteristics | (n = 2,764, 7.5%) | (n = 2,125, 5.8%) | (n = 1,32K, 3.6%) | (n = 5,396, 14.6%) | (n = 1,537, 4.2%) | (n = 5,777, 15.6%) | (n = 718, 1.9%) | (n = 576, 1.6%) |
| No. (%) of patients with co‐detection a | 833 (30.1) b | 432 (20.3) | 246 (18.6) | 375 (6.9) | 313 (20.4) | 1.136 (19.7) | 383 (53.3)b | 106 (18.4) |
| Sex | ||||||||
| Male:female | 1,507:1,257 | 1,050:1,075 | 676:645 | 2,506:2,890 | 722:815 | 2,891:2,886 | 389:329 | 285:291 |
| Clinical symptoms (OR c , 95%Cl) | ||||||||
| Fever | 2,422 | 1,653 | 1,043 | 4,455 | 948 | 3,430 | 559 | 473 |
| (3.40, 3.03‐3.82) | (1.61, 1.45‐1.79) | (1.71, 1.50‐1.96) | (2.35, 2.18‐2.53) | (0.71, 0.64‐0.79) | (0.61, 0.57‐0.64) | (1.59, 1.33‐1.90) | (2.08, 1.68‐2.58) | |
| Cough | 1.528 | 1.523 | 1.085 | 4.064 | 1.037 | 3.922 | 516 | 498 |
| (0.68, 0.63‐0.74) | (1.46, 1.33‐1.61) | (2.67, 2.32‐3.08) | (1.87, 1.75‐2.00) | (1.18, 1.06‐1.32) | (1.23, 1.16‐1.31) | (1.46, 1.24‐1.71) | (3.67, 2.89‐4.66) | |
| Runny nose | 1.500 | 1.224 | 912 | 3.088 | 1.019 | 3.867 | 486 | 363 |
| (0.97, 0.90‐1.05) | (1.12, 1.03‐1.23) | (1.87, 1.66‐2.11) | (1.12, 1.05‐1.18) | (1.65, 1.48‐1.84) | (1.81, 1.71‐1.92) | (1.74, 1.49‐2.04) | (1.41, 1.19‐1.67) | |
| Sore tliroat | 832 | 706 | 290 | 2.755 | 595 | 2.253 | 148 | 208 |
| (0.57, 0.53‐0.62) | (0.67, 0.61‐0.74) | (0.38, 0.33‐0.43) | (1.53, 1.44‐1.62) | (0.87, 0.78‐0.96) | (0.86, 0.81‐0.91) | (0.35, 0.29‐0.42) | (0.78, 0.65‐0.92) | |
| Chills | 269 | 244 | 107 | 1.644 | 213 | 681 | 34 | 82 |
| (0.48, 0.42‐0.54) | (0.58, 0.51‐0.67) | (0.40, 0.33‐0.48) | (2.33, 2.19‐2.49) | (0.73, 0.63‐0.85) | (0.57, 0.53‐0.62) | (0.23, 0.16‐0.32) | (0.76, 0.60‐0.96) | |
| Headache | 411 | 384 | 157 | 2.301 | 383 | 1.288 | 63 | 114 |
| (0.42, 0.37‐0.46) | (0.54, 0.48‐0.60) | (0.33, 0.28‐0.39) | (2.09, 1.97‐2.22) | (0.83, 0.74‐0.93) | (0.68, 0.64‐0.73) | (0.24, 0.18‐0.31) | (0.62, 0.50‐0.76) | |
| Myalgia | 245 | 275 | 122 | 2.156 | 336 | 959 | 29 | 95 |
| (0.31, 0.27‐0.35) | (0.48, 0.42‐0.55) | (0.33, 0.27‐0.40) | (2.60, 2.45‐2.76) | (0.93, 0.82‐1.05) | (0.62, 0.58‐0.67) | (0.14, 0.10‐0.20) | (0.65, 0.52‐0.82) | |
| Sputum | 838 | 955 | 755 | 1.841 | 546 | 2.293 | 316 | 311 |
| (0.78, 0.71‐0.84) | (1.52, 1.39‐1.66) | (2.50, 2.24‐2.80) | (0.93, 0.88‐0.99) | (1.00, 0.90‐1.11) | (1.23, 1.17‐1.31) | (1.44, 1.24‐1.67) | (2.16, 1.83‐2.54) | |
| Diarrhea | 11 | 6 | 12 | 14 | 6 | 20 | 1 | 2 |
| (1.06, 0.57‐1.96) | (0.74, 0.33‐1.67) | (2.54, 1.41‐4.60) | (0.65, 0.38‐1.13) | (1.03, 0.46‐2.35) | (0.90, 0.56‐1.45) | (0.36, 0.05‐2.60) | (0.92, 0.23‐3.71) |
a
Episodes of coinfection with >1 virus were excluded from the analysis of demographic and clinical feamres.
b
Co‐detection rates of HBoV and HAdV were higher than other viruses.
c
Odds ratios were calculated based on the multivariate logistic regression for correlation of each viruses and clinical symptoms.
This article is being made freely available through PubMed Central as part of the COVID-19 public health emergency response. It can be used for unrestricted research re-use and analysis in any form or by any means with acknowledgement of the original source, for the duration of the public health emergency.